ArticleBMC infectious diseases2025
Molecular detection of Leishmania major human infections in the Zinder area, Niger.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Evidence Gaps and Global Patterns in Leishmaniasis Control: A Scoping Review of Clinical, Diagnostic, and Treatment Strategies.Journal of parasitology research · 2026Review
- Molecular diagnostics for cutaneous leishmaniasis: progress towards fulfilling the WHO target product profile.Parasitology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundCutaneous Leishmaniasis (CL) is underreported in Sub-Saharan Africa. Only a few studies reported the use of molecular diagnostic methods for CL in the region, whereas reports of therapeutic outcomes are scarce.
methodsAn international consortium was established between local teams in the Zinder region of Niger and a referral centre for leishmaniasis in French Guiana. Specific training on CL diagnostic was provided by the Guianese team to Nigerien health workers. All consenting patients with clinically suspected CL lesions were enrolled. Samples were made for parasitological smear and PCR on cotton swabs. Then, participants were treated as per local protocol with oral metronidazole for 14 days and were followed for 4 months.
resultsIn total, 59 clinically suspected CL cases were included, among whom 33 (56%) were confirmed by PCR and/or by microscopy, including 21 men and 22 women, 23 minors and 10 adults. 32 (97%) of them presented with ulcers (including 12 with ulcers and nodules). The median number of lesions was 2 [IQR 1-3]. The most frequent location of lesions was the lower limbs (21/33, 63.6%), followed by the upper limbs (14/33, 42.4%). One mucosal involvement was reported but unconfirmed with PCR. The efficacy of oral metronidazole was 90.9% (30/33) among confirmed cases and 76.3% (45/59) in the overall study population. The documented species was Leishmania major.
conclusionsThis is the first report of PCR-proven human CL in Niger, and the first report of a human CL case in the Zinder area for more than a century. Molecular techniques confirmed the circulation of L. major in this area, which until now had only been determined by isoenzymes analysis. Presenting CL patients were very young. Treatment outcomes with metronidazole were encouraging. This prompts for a formal evaluation of the efficacy of this drug, ideally in a randomized controlled trial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.